市場調查報告書

全球病毒載體和質體DNA製造市場:按載體類型、工作流程、應用、末端應用、疾病之市場規模、占比、趨勢、區域預測(2020年∼2027年)

Viral Vectors & Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector (Lentivirus, Retrovirus), By Workflow, By Application, By End Use, By Disease, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 786001
出版日期 內容資訊 英文 250 Pages
商品交期: 2-3個工作天內
價格
全球病毒載體和質體DNA製造市場:按載體類型、工作流程、應用、末端應用、疾病之市場規模、占比、趨勢、區域預測(2020年∼2027年) Viral Vectors & Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector (Lentivirus, Retrovirus), By Workflow, By Application, By End Use, By Disease, And Segment Forecasts, 2020 - 2027
出版日期: 2020年02月14日內容資訊: 英文 250 Pages
簡介

預估全球病毒載體和質體DNA製造市場,在預測期間中將以14.52%的CAGR成長,於2027年達11億美元規模。基因治療臨床試驗中,有近70%的治療使用載體,載體的需求已超過其供應率。因此由生物科技及藥廠啟動的基於尖端治療之發現計畫數增加,有望推動對該市場的投資。

本報告研究全球病毒載體和質體DNA製造市場,彙整市場趨勢、課題、企業生產能力和產量,提供按載體類型、工作流程、應用、末端應用、疾病、區域的市場分析,以及競爭情勢、主要企業簡介等情報。

目錄

第1章 摘要整理

  • 市場概述

第2章 研究方法

  • 情報採購
  • 情報與數據分析
  • 市場規劃與驗證

第3章 市場變數、趨勢、範圍

  • 市場區分和範圍
  • 病毒載體的生產:階段性課題和解決方案
  • 載體類型:普及與成長展望MAPPING
  • 主要產業企業:普及與成長展望MAPPING
  • 製造商展望
  • 按因素的SWOT分析(政治、法律、經濟、技術)
  • 產業分析:波特五力分析

第4章 病毒載體生產能力MAPPING分析

  • CMO生產能力
  • 內部製造商的生產能力
  • 無塵室套室設施:領先病毒載體製造商
  • 主要企業:位置MAPPING和既有生產能力
  • AAV、LV載體候補開發組織
  • 病毒載體/基因/細胞療法領域之主要參與者的CMO哺乳類細胞培養能力:主要統計
  • 哺乳類細胞株:生產能力和投資
  • 具包含載體基礎治療藥候補之投資組合的企業名單
  • 載體製造商名單

第5章 病毒載體生產:成本

  • 成本模型

第6章 生產和產量分析

  • 生產產量:Biomarin、Spark Therapeutics、Solid Biosciences
  • 增加、達成目標劑量之載體生產的各種方法
  • 使用不同細胞培養系統的每日載體總量和產量
  • 優化細胞、基因治療之病毒載體製造所採取的措施
  • 根據批次大小的病毒載體之大型、小型生產分析
  • 小型(10∼50L)腺病毒載體製造的一般方法

第7章 製程經濟考量和挑戰

  • 製造技術的進步
  • 基線程序的CoG分析
  • 監管期望
  • 病毒載體供應基因治療方法

第8章 策略聯盟

  • 基因治療領域的合適投資時機
  • 市場規模擴大的策略方法
  • 合作模型
  • 病毒載體製造市場的合作

第9章 市場分析:按載體類型

  • 趨勢分析
  • 腺病毒
  • 反轉錄病毒
  • 質體DNA
  • AAV
  • 慢病毒
  • 其他

第10章 市場分析:按工作流程

  • 趨勢分析
  • 上游製造
    • 載體增幅和擴大
    • 載體回收/收集
  • 下游製造
    • 純化
    • 充填完成

第11章 市場分析:按應用

  • 趨勢分析
  • 反義和RNAi療法
  • 細胞療法
  • 基因治療
  • 疫苗學

第12章 市場分析:按末端應用

  • 趨勢分析
  • 藥廠和生物醫藥企業
  • 研究機構

第13章 市場分析:按疾病

  • 趨勢分析
  • 癌症
  • 遺傳疾病
  • 傳染病
  • 其他

第14章 市場分析:按區域

  • 市場占比
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第15章 競爭情勢

  • 策略框架
  • 市場參與企業分類
  • 企業簡介:CMO
  • 企業簡介:內部製造

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-2-68038-695-0

The global viral vectors & plasmid DNA manufacturing market size is expected to reach USD 1.1 billion by 2027, exhibiting a 14.52% CAGR, during the forecast period, according to a new report by Grand View Research, Inc. Currently, more than 700 cell and gene therapies are in clinical trials and vectors are used in nearly 70% of these therapies. As a result, demand for vectors has exceeded the supply rate. Thus, an increase in the number of advanced therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive investments in the market.

Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.

Considering growing opportunities in vector production, the Original Equipment Manufacturers (OEMs) are making focused efforts to gain a competitive advantage in the market. For example, the introduction of ready-to-run factory-in-a-box to accelerate the production of virus-based therapeutics by GE healthcare, as a solution to simplify and advance the manufacturing process.

Further key findings from the report suggest:

  • With high usage, attributed to its ability of high titer production and capability to induce strong humoral and T cell responses in various research applications, adenovirus held the leading viral vectors and plasmid DNA manufacturing market share in terms of revenue, in 2019
  • Lentivirus vector is anticipated to register the fastest CAGR over the forecast period. This can be attributed to constant growth in the lentivirus-based gene therapy pipeline program
  • Downstream processing held the dominant revenue share in 2019, owing to the fact that this process involves purification steps that account for the majority of the overall manufacturing cost. Employment of expensive equipment and requirement of trained personnel for product recovery has further driven revenue in the segment
  • Antisense and RNAi therapy production is estimated as the key application of vector manufacturing, resulting in the dominance of this segment over other applications
  • The high adoption rate of viruses for aptamers and oligonucleotide development in comparison to other applications has driven revenue in antisense and RNAi therapy segment
  • High usage of vectors for therapeutic production have contributed to the large revenue share of pharmaceutical and biopharmaceutical companies. The number of biotech companies employing vector for therapies production is anticipated to multiply over the forecast period
  • Presence of a substantial number of advanced therapy products in the pipeline targeting various cancer forms has accelerated revenue share of the cancer segment over the years
  • Given the high number of biotech entities in parts of U.S., such as in California and Massachusetts, North America has maintained its dominance in terms of revenue. In addition, the active participation of regulatory bodies in improving the regulatory scenario for the market launch of advanced therapies has facilitated the high usage of vectors in U.S.
  • Merck, Cobra Biologics, Novasep, and uniQure N.V., are some key participants that are geared towards capitalizing the untapped opportunities in the market

Table of Contents

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines
      • 3.1.1.2 Technological advancements in manufacturing vectors
      • 3.1.1.3 Highly competitive market and various strategies undertaken by market entities
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
    • 3.1.3 Challenge analysis
      • 3.1.3.1 Production capacity challenges
      • 3.1.3.1 Manufacturing challenges pertaining to large-scale production of vectors
    • 3.1.4 Opportunity analysis
      • 3.1.4.1 Facility expansion for cell and gene therapies
  • 3.2 Viral Vector Production: Stepwise Challenges & Solutions
    • 3.2.1 Plasmid Production: Challenges & Solutions
    • 3.2.2 Host Cell Production & Banking Needs
    • 3.2.3 Viral Vector Production, F&F: Challenges & Solutions
    • 3.2.4 Viral Vector Production, Analytics: Challenges & Solutions
  • 3.3 Penetration & Growth Prospect Mapping for Vector Type, 2019
  • 3.4 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
  • 3.5 Manufacturer's Landscape
  • 3.6 Viral Vector & Plasmid DNA Manufacturing Market-SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • 3.7 Industry Analysis - Porter's

Chapter 4 Viral Vector Production Capacity Mapping Analysis

  • 4.1 CMOs Capacity for Viral Vector Manufacturing
  • 4.2 In-house Manufacturers Capacity for Viral Vector Manufacturing
  • 4.3 Cleanroom Suites Facilities: Leading Viral Vector Manufacturers
  • 4.4 Prominent Players: Location Mapping & existing Capacities
  • 4.5 AAV and LV vector candidate developing organizations
  • 4.6 CMO Mammalian Cell Culture Capacity of Key Players in Viral Vector/Gene/Cell Therapy Space: Key Statistics
  • 4.7 Mammalian cell lines: Capacity & Investments
    • 4.7.1 Small Scale Companies: Mammalian Cell Culture Capacities
    • 4.7.2 Medium scale companies: Mammalian cell culture capacities
    • 4.7.3 Large scale companies: Mammalian cell culture capacities
  • 4.8 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
  • 4.9 List of Vector Manufacturers

Chapter 5 Viral Vector Production: Costs

  • 5.1 Cost Models
    • 5.1.1 Campaign model
    • 5.1.2 Day rate model
    • 5.1.3 Hybrid model

Chapter 6 Viral Vector Production & Yield Analysis

  • 6.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
  • 6.2 Various Modes of Vector Production to increase & achieve Target Doses
    • 6.2.1 Adenoviral vectors
    • 6.2.2 γ- retroviral (MLV - murineleukemia virus) vectors
    • 6.2.3 Lentiviral vectors
    • 6.2.4 AAV vectors
    • 6.2.5 rAAV vectors
      • 6.2.5.1 rAAV Production : Challenges & Solutions
  • 6.3 Total vector quantity produced per day and yield volume using different cell culture systems
  • 6.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
  • 6.5 Analysis of large- and small-scale production of viral vectors based on batch size
    • 6.5.1 Small-scale/laboratory-scale cell culture systems
    • 6.5.2 Large-scale cell culture systems
  • 6.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing

Chapter 7 Viral Vector Manufacturing: Process Economic Considerations & Challenges

  • 7.1 Technological Advances in Manufacturing
    • 7.1.1 Stable Producer Cell Lines
    • 7.1.2 Transient production
    • 7.1.3 Lentiviral vector production process
      • 7.1.3.1 Developments in LentiVector platform
  • 7.2 CoGs Analysis of the Baseline Process
    • 7.2.1 Raw Material
    • 7.2.2 Labor costs
    • 7.2.3 Process costs
  • 7.3 Regulatory Expectations
  • 7.4 Approaches for Viral Vector Supply Gene Therapy
    • 7.4.1 Gene Therapy Manufacturing Facilities: Trends & Types
    • 7.4.2 Gene Therapy Road Map: Key External Trends

Chapter 8 Viral Vector Manufacturing Market: Strategic Alliances

  • 8.1 Is The Time Right To Invest In Gene Therapy Sector?
  • 8.2 Strategic Approaches for Market Scale-Up
  • 8.3 Partnership Models
    • 8.3.1 Acquisition
    • 8.3.2 Minority interest (ownership)
    • 8.3.3 Joint venture
    • 8.3.4 Alliance
    • 8.3.5 Franchise
  • 8.4 Collaborations in Viral Vector Manufacturing Market
    • 8.4.1 Breakthrough Growth: Lonza, Oxford BioMedica & Others

Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis

  • 9.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis
  • 9.2 Adenovirus
    • 9.2.1 Global adenovirus market, 2016 - 2027 (USD Million)
  • 9.3 Retrovirus
    • 9.3.1 Global retrovirus market, 2016 - 2027 (USD Million)
  • 9.4 Plasmid DNA
    • 9.4.1 Global plasmid DNA market, 2016 - 2027 (USD Million)
  • 9.5 AAV
    • 9.5.1 Global AAV market, 2016 - 2027 (USD Million)
  • 9.6 Lentivirus
    • 9.6.1 Global lentivirus market, 2016 - 2027 (USD Million)
  • 9.7 Other Vectors
    • 9.7.1 Global other vectors market, 2016 - 2027 (USD Million)

Chapter 10 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis

  • 10.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis
  • 10.2 Upstream Manufacturing
    • 10.2.1 Global upstream manufacturing market, 2016 - 2027 (USD Million)
    • 10.2.2 Vector amplification & expansion
      • 10.2.2.1 Global vector amplification & expansion market, 2016 - 2027 (USD Million)
    • 10.2.3 Vector recovery/harvesting
      • 10.2.3.1 Global vector recovery/harvesting market, 2016 - 2027 (USD Million)
  • 10.3 Downstream Manufacturing
    • 10.3.1 Global downstream manufacturing market, 2016 - 2027 (USD Million)
    • 10.3.2 Purification
      • 10.3.2.1 Global purification market, 2016 - 2027 (USD Million)
    • 10.3.3 Fill Finish
      • 10.3.3.1 Global fill finish market, 2016 - 2027 (USD Million)

Chapter 11 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis

  • 11.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis
  • 11.2 Antisense & RNAi Therapy
    • 11.2.1 Market for antisense, & RNAi therapy, 2016 - 2027 (USD Million)
  • 11.3 Cell Therapy
    • 11.3.1 Market for cell therapy, 2016 - 2027 (USD Million)
  • 11.4 Gene Therapy
    • 11.4.1 Market for gene therapy, 2016 - 2027 (USD Million)
  • 11.5 Vaccinology
    • 11.5.1 Market for vaccinology, 2016 - 2027 (USD Million)

Chapter 12 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis

  • 12.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis
  • 12.2 Pharmaceutical and Biopharmaceutical Companies
    • 12.2.1 Market for pharmaceutical and biopharmaceutical companies, 2016 - 2027 (USD Million)
  • 12.3 Research Institutes
    • 12.3.1 Market for research institutes, 2016 - 2027 (USD Million)

Chapter 13 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis

  • 13.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis
  • 13.2 Cancer
    • 13.2.1 Market for cancer, 2016 - 2027 (USD Million)
  • 13.3 Genetic Disorders
    • 13.3.1 Market for genetic disorders, 2016 - 2027 (USD Million)
  • 13.4 Infectious Diseases
    • 13.4.1 Market for infectious diseases, 2016 - 2027 (USD Million)
  • 13.5 Others
    • 13.5.1 Market for other diseases, 2016 - 2027 (USD Million)

Chapter 14 Market Categorization: Regional Estimates & Trend Analysis, by Product

  • 14.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2019 & 2027
  • 14.2 North America
    • 14.2.1 North America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
    • 14.2.2 U.S.
      • 14.2.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.2.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.2.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.2.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.2.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
    • 14.2.3 Canada
      • 14.2.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.2.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.2.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.2.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.2.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
  • 14.3 Europe
    • 14.3.1 Europe viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
    • 14.3.2 Germany
      • 14.3.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.3.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.3.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.3.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.3.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
    • 14.3.3 U.K.
      • 14.3.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.3.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.3.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.3.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.3.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
  • 14.4 Asia Pacific
    • 14.4.1 Asia Pacific viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
    • 14.4.2 Japan
      • 14.4.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.4.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.4.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.4.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.4.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
    • 14.4.3 China
      • 14.4.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.4.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.4.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.4.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.4.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
  • 14.5 Latin America
    • 14.5.1 Latin America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
    • 14.5.2 Brazil
      • 14.5.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.5.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.5.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.5.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.5.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
  • 14.6 MEA
    • 14.6.1 MEA viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
    • 14.6.2 South Africa
      • 14.6.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
      • 14.6.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
      • 14.6.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
      • 14.6.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
      • 14.6.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)

Chapter 15 Competitive Landscape

  • 15.1 Strategy Framework
  • 15.2 Market Participation Categorization
  • 15.3 Company Profiles: Contract Manufacturing Organizations (CMOs)
    • 15.3.1 Merck KGaA
      • 15.3.1.1 Company overview
      • 15.3.1.1.1 Sigma-Aldrich Co. LLC
      • 15.3.1.2 Financial performance
      • 15.3.1.3 Product benchmarking
      • 15.3.1.4 SWOT analysis
      • 15.3.1.5 Operational capacity
      • 15.3.1.6 Strategic initiatives
    • 15.3.2 Lonza
      • 15.3.2.1 Company overview
      • 15.3.2.2 Financial performance
      • 15.3.2.3 Product benchmarking
      • 15.3.2.4 SWOT analysis
      • 15.3.2.5 Operational capacity
      • 15.3.2.6 Strategic initiatives
    • 15.3.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
      • 15.3.3.1 Company overview
      • 15.3.3.2 Financial performance
      • 15.3.3.3 Product benchmarking
      • 15.3.3.4 SWOT analysis
      • 15.3.3.5 Operational capacity
      • 15.3.3.6 Strategic initiatives
    • 15.3.4 Cobra Biologics Ltd.
      • 15.3.4.1 Company overview
      • 15.3.4.2 Financial performance
      • 15.3.4.3 Product benchmarking
      • 15.3.4.4 SWOT analysis
      • 15.3.4.5 Operational capacity
      • 15.3.4.6 Strategic initiatives
    • 15.3.5 Brammer Bio
      • 15.3.5.1 Company overview
      • 15.3.5.2 Financial performance
      • 15.3.5.3 Product benchmarking
      • 15.3.5.4 SWOT analysis
      • 15.3.5.5 Operational capacity
      • 15.3.5.6 Strategic initiatives
    • 15.3.6 Waisman Biomanufacturing
      • 15.3.6.1 Company overview
      • 15.3.6.2 Financial performance
      • 15.3.6.3 Product benchmarking
      • 15.3.6.4 SWOT analysis
      • 15.3.6.5 Operational capacity
      • 15.3.6.6 Strategic initiatives
    • 15.3.7 Genezen
      • 15.3.7.1 Company overview
      • 15.3.7.2 Product benchmarking
      • 15.3.7.3 SWOT analysis
      • 15.3.7.4 Operational capacity
      • 15.3.7.5 Strategic initiatives
    • 15.3.8 YPOSKESI
      • 15.3.8.1 Company overview
      • 15.3.8.2 Financial performance
      • 15.3.8.3 Product benchmarking
      • 15.3.8.4 SWOT analysis
      • 15.3.8.5 Operational capacity
      • 15.3.8.6 Strategic initiatives
    • 15.3.9 Advanced BioScience Laboratories, Inc. (ABL, Inc.)
      • 15.3.9.1 Company overview
      • 15.3.9.2 Financial performance
      • 15.3.9.3 Product benchmarking
      • 15.3.9.4 SWOT analysis
      • 15.3.9.5 Operational capacity
      • 15.3.9.6 Strategic initiatives
    • 15.3.10 Novasep Holding S.A.S
      • 15.3.10.1 Company overview
      • 15.3.10.2 Product benchmarking
      • 15.3.10.3 SWOT analysis
      • 15.3.10.4 Operational capacity
      • 15.3.10.5 Strategic initiatives
    • 15.3.11 ATVIO Biotech Ltd
      • 15.3.11.1 Company overview
      • 15.3.11.2 Financial performance
      • 15.3.11.3 Product benchmarking
      • 15.3.11.4 SWOT analysis
      • 15.3.11.5 Operational capacity
      • 15.3.11.6 Strategic initiatives
    • 15.3.12 Vigene Biosciences, Inc.
      • 15.3.12.1 Company overview
      • 15.3.12.2 Financial performance
      • 15.3.12.3 Product benchmarking
      • 15.3.12.4 SWOT analysis
      • 15.3.12.5 Operational capacity
      • 15.3.12.6 Strategic initiatives
    • 15.3.13 General Electric Company (GE Healthcare)
      • 15.3.13.1 Company overview
      • 15.3.13.2 Financial performance
      • 15.3.13.3 Product benchmarking
      • 15.3.13.4 SWOT analysis
      • 15.3.13.5 Operational capacity
      • 15.3.13.6 Strategic initiatives
    • 15.3.14 CEVEC Pharmaceuticals GmbH
      • 15.3.14.1 Company overview
      • 15.3.14.2 Financial performance
      • 15.3.14.3 Product benchmarking
      • 15.3.14.4 SWOT analysis
      • 15.3.14.5 Operational capacity
      • 15.3.14.6 Strategic initiatives
    • 15.3.15 Batavia Biosciences B.V.
      • 15.3.15.1 Company overview
      • 15.3.15.2 Financial performance
      • 15.3.15.3 Product benchmarking
      • 15.3.15.4 SWOT analysis
      • 15.3.15.5 Operational capacity
      • 15.3.15.6 Strategic initiatives
    • 15.3.16 Biovian Oy
      • 15.3.16.1 Company overview
      • 15.3.16.2 Financial performance
      • 15.3.16.3 Product benchmarking
      • 15.3.16.4 SWOT analysis
      • 15.3.16.5 Operational capacity
      • 15.3.16.6 Strategic initiatives
    • 15.3.17 Wuxi AppTec Co., Ltd.
      • 15.3.17.1 Company overview
      • 15.3.17.2 Financial performance
      • 15.3.17.3 Product benchmarking
      • 15.3.17.4 SWOT analysis
      • 15.3.17.5 Operational capacity
      • 15.3.17.6 Strategic initiatives
    • 15.3.18 VGXI, Inc.
      • 15.3.18.1 Company overview
      • 15.3.18.2 Financial performance
      • 15.3.18.3 Product benchmarking
      • 15.3.18.4 SWOT analysis
      • 15.3.18.5 Operational capacity
      • 15.3.18.6 Strategic initiatives
    • 15.3.19 Paragon Bioservices, Inc
      • 15.3.19.1 Company overview
      • 15.3.19.2 Financial performance
      • 15.3.19.3 Product benchmarking
      • 15.3.19.4 SWOT analysis
      • 15.3.19.5 Operational capacity
      • 15.3.19.6 Strategic initiatives
    • 15.3.20 Miltenyi Biotec GmbH
      • 15.3.20.1 Company overview
      • 15.3.20.2 Lentigen Technology, Inc.
      • 15.3.20.3 Financial performance
      • 15.3.20.4 Product benchmarking
      • 15.3.20.5 SWOT analysis
      • 15.3.20.6 Operational capacity
      • 15.3.20.7 Strategic initiatives
    • 15.3.21 SIRION Biotech GmbH
      • 15.3.21.1 Company overview
      • 15.3.21.2 Financial performance
      • 15.3.21.3 Product benchmarking
      • 15.3.21.4 SWOT analysis
      • 15.3.21.5 Operational capacity
      • 15.3.21.6 Strategic initiatives
    • 15.3.22 Virovek Incorporation
      • 15.3.22.1 Company overview
      • 15.3.22.2 Financial performance
      • 15.3.22.3 Product benchmarking
      • 15.3.22.4 SWOT analysis
      • 15.3.22.5 Operational capacity
      • 15.3.22.6 Strategic initiatives
    • 15.3.23 BioNTech IMFS GmbH
      • 15.3.23.1 Company overview
      • 15.3.23.2 Financial performance
      • 15.3.23.3 Product benchmarking
      • 15.3.23.4 SWOT analysis
      • 15.3.23.5 Operational capacity
    • 15.3.24 VIVEbiotech S.L.
      • 15.3.24.1 Company overview
      • 15.3.24.2 Financial performance
      • 15.3.24.3 Product benchmarking
      • 15.3.24.4 SWOT analysis
      • 15.3.24.5 Operational capacity
      • 15.3.24.6 Strategic initiatives
    • 15.3.25 Creative Biogene
      • 15.3.25.1 Company overview
      • 15.3.25.2 Product benchmarking
      • 15.3.25.3 SWOT analysis
    • 15.3.26 Vibalogics GmbH
      • 15.3.26.1 Company overview
      • 15.3.26.2 Product benchmarking
      • 15.3.26.3 SWOT analysis
      • 15.3.26.4 Operational capacity
      • 15.3.26.5 Strategic initiatives
  • 15.4 Company Profiles: In-house Manufacturers
    • 15.4.1 Cell and Gene Therapy Catapult
      • 15.4.1.1 Company overview
      • 15.4.1.2 Product benchmarking
      • 15.4.1.3 SWOT analysis
      • 15.4.1.4 Operational capacity
      • 15.4.1.5 Strategic initiatives
    • 15.4.2 BlueBird Bio
      • 15.4.2.1 Company overview
      • 15.4.2.2 Financial performance
      • 15.4.2.3 Product benchmarking
      • 15.4.2.4 SWOT analysis
      • 15.4.2.5 Operational capacity
      • 15.4.2.6 Strategic initiatives
    • 15.4.3 Addgene, Inc.
      • 15.4.3.1 Company overview
      • 15.4.3.2 Financial performance
      • 15.4.3.3 Product benchmarking
      • 15.4.3.4 SWOT analysis
      • 15.4.3.5 Operational capacity
      • 15.4.3.6 Strategic initiatives
    • 15.4.4 Aldevron, L.L.C.
      • 15.4.4.1 Company overview
      • 15.4.4.2 Financial performance
      • 15.4.4.3 Product benchmarking
      • 15.4.4.4 SWOT analysis
      • 15.4.4.5 Operational capacity
      • 15.4.4.6 Strategic initiatives
    • 15.4.5 Audentes Therapeutics
      • 15.4.5.1 Company overview
      • 15.4.5.2 Financial performance
      • 15.4.5.3 Product benchmarking
      • 15.4.5.4 SWOT analysis
      • 15.4.5.5 Operational capacity
      • 15.4.5.6 Strategic initiatives
    • 15.4.6 BioMarin Pharmaceutical
      • 15.4.6.1 Company overview
      • 15.4.6.2 Financial performance
      • 15.4.6.3 Product benchmarking
      • 15.4.6.4 SWOT analysis
      • 15.4.6.5 Operational capacity
      • 15.4.6.6 Strategic initiatives

List of Tables

  • TABLE 1 Location Mapping
  • TABLE 2 Production yields of rAAV vectors using different production systems
  • TABLE 3 Large-scale production of MLV vectors for clinical applications
  • TABLE 4 Overview of costs involved in cell therapy development
  • TABLE 5 Common raw/starting materials for viral vector manufacturing
  • TABLE 6 Sensitivity of baseline process to failure rates during cell therapy production
  • TABLE 7 Approved cell therapy products
  • TABLE 8 Approved gene therapy products
  • TABLE 9 Clinical trials in cancer gene therapy
  • TABLE 10 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 11 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 12 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 13 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 14 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 15 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 16 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 17 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 18 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 19 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 20 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 21 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 22 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 23 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 24 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 25 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 26 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 27 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 28 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 29 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 30 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 31 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 32 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 33 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 34 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 35 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 36 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 37 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 38 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 39 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 40 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 41 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 42 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 43 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 44 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 44 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 45 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 46 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 47 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 48 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 49 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 50 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 51 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 52 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 53 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 54 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 55 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 56 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 57 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 58 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 59 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 60 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 61 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 62 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 63 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 64 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 65 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 66 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 67 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 68 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 69 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 70 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 71 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 72 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 73 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 74 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 75 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 76 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 77 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 78 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 79 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 80 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 81 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 82 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 83 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 84 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 85 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 86 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 87 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 88 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 89 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 90 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 91 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 92 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 93 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
  • TABLE 94 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 95 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 96 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 97 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 98 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
  • TABLE 99 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain-based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Gene therapies in development (at all stages) per disease group, 2016
  • FIG. 12 Pipeline analysis for viral vector manufacturing
  • FIG. 13 Pipeline analysis for viral vector manufacturing
  • FIG. 14 Pipeline analysis for viral vector manufacturing
  • FIG. 15 Recent and expected upcoming US/EU approvals for gene transfer-mediated programs
  • FIG. 16 Market restraint relevance analysis (Current & future impact)
  • FIG. 17 Various ethical questions raised by gene therapy
  • FIG. 18 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
  • FIG. 19 Plasmid Production: Challenges & Solutions
  • FIG. 20 Host Cell Production & Banking Needs
  • FIG. 21 Viral Vector Production, F&F: Challenges & Solutions
  • FIG. 22 Viral Vector Production, Analytics: Challenges & Solutions
  • FIG. 23 Penetration & growth prospect mapping for vector type, 2019
  • FIG. 24 Penetration & growth prospect mapping for prominent industry players, 2019
  • FIG. 25 Viral Vector Manufacturing Landscape
  • FIG. 26 SWOT analysis, by factor (Political & legal, economic, and technological)
  • FIG. 27 Porter's Five Forces Analysis
  • FIG. 28 Capacity Mapping: CMOs in Viral Vector Manufacturing Market
  • FIG. 29 Capacity Mapping: In-house Manufacturers in Viral Vector Manufacturing Market
  • FIG. 30 Cleanroom Suites in Viral Vector Manufacturing Market
  • FIG. 31 AAV and LV vector candidate developing organizations
  • FIG. 32 Historical & estimated CMO mammalian cell culture capacity of key players in viral vector/gene/cell therapy space
  • FIG. 33 Investments by key players to expand their production capacity for mammalian cells
  • FIG. 34 Companies with small scale bioreactors for mammalian cell culture
  • FIG. 35 Companies with medium scale bioreactors for mammalian cell culture
  • FIG. 36 Companies with large scale bioreactors for mammalian cell culture
  • FIG. 37 List of companies with portfolio comprising vector-based therapeutic candidates
  • FIG. 38 List of vector manufacturers
  • FIG. 39 Comparison of costs estimated by campaign, day rate, and hybrid models
  • FIG. 40 Campaign model for viral vector production
  • FIG. 41 Day rate model for viral vector production
  • FIG. 42 Hybrid model for viral vector production
  • FIG. 43 Company-wise: Vector yields
  • FIG. 44 Prevailing Technologies for AAV Production
  • FIG. 45 rAAV Production : Challenges & Solutions
  • FIG. 46 iCELLis systems: Productivities
  • FIG. 47 Small- & large-scale cell culture systems for production of viral vectors
  • FIG. 48 Process flow diagram for common practices for small-scale (10-50 L) adenoviral vector purification
  • FIG. 49 Comparison of viral titers obtained from different LVV production methods
  • FIG. 50 Lentiviral Vector Clinical Trials, By year and Phase
  • FIG. 51 Breakdown of CoGs per process for cell therapy manufacture
  • FIG. 52 Progression of cGMP compliance at different product development stages
  • FIG. 53 Standardization & Regulatory Challenges
  • FIG. 54 Gene Therapy Manufacturing Facilities: Trends & Types
  • FIG. 55 Gene Therapy Road Map: Key External Trends
  • FIG. 56 Strategic Approaches for Market Scale-Up
  • FIG. 57 Viral vector & plasmid DNA manufacturing market: Vector type outlook key takeaways
  • FIG. 58 Global viral vector & plasmid DNA manufacturing market: Vector type movement analysis
  • FIG. 59 Global adenovirus market, 2016 - 2027 (USD Million)
  • FIG. 60 Global retrovirus market, 2016 - 2027 (USD Million)
  • FIG. 61 Global plasmid DNA market, 2016 - 2027 (USD Million)
  • FIG. 62 Global AAV market, 2016 - 2027 (USD Million)
  • FIG. 63 Global lentivirus market, 2016 - 2027 (USD Million)
  • FIG. 64 Global other vectors market, 2016 - 2027 (USD Million)
  • FIG. 65 Viral vector & plasmid DNA manufacturing market: Workflow outlook key takeaways
  • FIG. 66 Global viral vector & plasmid DNA manufacturing market: Workflow movement analysis
  • FIG. 67 Global upstream manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 68 Global vector amplification & expansion market, 2016 - 2027 (USD Million)
  • FIG. 69 Global vector recovery/harvesting market, 2016 - 2027 (USD Million)
  • FIG. 70 Global downstream manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 71 Global purification market, 2016 - 2027 (USD Million)
  • FIG. 72 Global fill finish market, 2016 - 2027 (USD Million)
  • FIG. 73 Viral vector & plasmid DNA manufacturing market: Application outlook key takeaways
  • FIG. 74 Global viral vector & plasmid DNA manufacturing market: Application movement analysis
  • FIG. 75 Global viral vector & plasmid DNA manufacturing market for antisense, & RNAi therapy, 2016 - 2027 (USD Million)
  • FIG. 76 Global viral vector & plasmid DNA manufacturing market for cell therapy, 2016 - 2027 (USD Million)
  • FIG. 77 Global viral vector & plasmid DNA manufacturing market for gene therapy, 2016 - 2027 (USD Million)
  • FIG. 78 Strengths and weaknesses of viral vector vaccines
  • FIG. 79 Global viral vector & plasmid DNA manufacturing market for vaccinology, 2016 - 2027 (USD Million)
  • FIG. 80 Viral vector & plasmid DNA manufacturing market: End-use outlook key takeaways
  • FIG. 81 Global viral vector & plasmid DNA manufacturing market: End-use movement analysis
  • FIG. 82 Global viral vector & plasmid DNA manufacturing market for pharmaceutical and biopharmaceutical companies, 2016 - 2027 (USD Million)
  • FIG. 83 Global viral vector & plasmid DNA manufacturing market for research institutes, 2016 - 2027 (USD Million)
  • FIG. 84 Viral vector & plasmid DNA manufacturing market: Disease outlook key takeaways
  • FIG. 85 Global viral vector & plasmid DNA manufacturing market: Disease movement analysis
  • FIG. 86 Global viral vector & plasmid DNA manufacturing market for cancer, 2016 - 2027 (USD Million)
  • FIG. 87 Global viral vector & plasmid DNA manufacturing market for genetic disorders, 2016 - 2027 (USD Million)
  • FIG. 88 Global viral vector & plasmid DNA manufacturing market for infectious diseases, 2016 - 2027 (USD Million)
  • FIG. 89 Global viral vector & plasmid DNA manufacturing market for other diseases, 2016 - 2027 (USD Million)
  • FIG. 90 Regional market place: Key takeaway
  • FIG. 91 Viral vector & plasmid DNA manufacturing market: Regional outlook, 2019 & 2027
  • FIG. 92 North America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 93 U.S. viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 94 Canada viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 95 Europe viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 96 Germany viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 97 U.K. viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 98 Asia Pacific viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 99 Japan viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 100 China viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 101 Latin America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 102 Brazil viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 103 MEA viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 104 South Africa viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
  • FIG. 105 Strategy framework
  • FIG. 106 Market participation categorization
  • FIG. 107 SWOT analysis: Merck
  • FIG. 108 SWOT analysis: Lonza
  • FIG. 109 SWOT analysis: FUJIFILM
  • FIG. 110 SWOT analysis: Cobra Biologics
  • FIG. 111 SWOT analysis: Brammer Bio
  • FIG. 112 SWOT analysis: Waisman Biomanufacturing
  • FIG. 113 SWOT analysis: Genezen
  • FIG. 114 SWOT analysis: YPOSKESI
  • FIG. 115 SWOT analysis: ABL
  • FIG. 116 SWOT analysis: Novasep
  • FIG. 117 SWOT analysis: ATVIO
  • FIG. 118 SWOT analysis: Vigene Biosciences
  • FIG. 119 SWOT analysis: GE Healthcare
  • FIG. 120 SWOT analysis: CEVEC
  • FIG. 121 SWOT analysis: Batavia Biosciences
  • FIG. 122 SWOT analysis: Biovian
  • FIG. 123 SWOT analysis: WuXi AppTec
  • FIG. 124 SWOT analysis: VGXI
  • FIG. 125 SWOT analysis: Paragon Bioservices, Inc.
  • FIG. 126 SWOT analysis: Lentigen Technology
  • FIG. 127 SWOT analysis: Sirion-Biotech
  • FIG. 128 SWOT analysis: VIROVEK
  • FIG. 129 SWOT analysis: BioNTech
  • FIG. 130 SWOT analysis: VIVE biotech
  • FIG. 131 SWOT analysis: Creative Biogene
  • FIG. 132 SWOT analysis: Vibalogics
  • FIG. 133 SWOT analysis: Cell and Gene Therapy Catapult
  • FIG. 134 SWOT analysis: BlueBird Bio
  • FIG. 135 SWOT analysis: Addgene
  • FIG. 136 SWOT analysis: Aldevron
  • FIG. 137 SWOT analysis: Audentes
  • FIG. 138 SWOT analysis: BioMarin Pharmaceutical